Antiplatelet agents fail to benefit critically ill adults with COVID-19 - Healio

Compared with no antiplatelet therapy, aspirin and P2Y12 inhibitors did not improve the number of organ support-free days in critically ill patients with COVID-19, according to results of the REMAP-CAP trial published in JAMA.The researchers enrolled 1,557 cr…

Source/Disclosures Disclosures: Bradbury reports receiving personal fees from Ablynx, Amgen, Bayer, Bristol Myers Squibb/Pfizer, Eli Lilly, Grifols, Janssen, Novartis and Portola. Please see the… [+5056 chars]

full article...